Lys Therapeutics is a biotherapeutic company focused on developing treatments for neurological diseases. Their main drug-candidate is a first-in-class monoclonal antibody that works by preventing the binding of tPA on the GluN1 subunit of NMDA receptors, without blocking the physiological function of NMDAr. This helps to halt downstream deleterious cellular pathways, reestablish tight junctions, and restore the blood-brain barrier function. This groundbreaking mechanism of action has been...